Scholarlink

<p>The introduction of incretin mimetic drugs, particularly Glucagon-Like Peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, as well as the dual GIP and GLP-1 receptor agonist tirzepatide, has significantly transformed the therapeutic approach to obesity by enabling clinically meaningful weight loss along with associated cardiometabolic benefits. However, obesity remains a chronic, multifactorial, and relapsing condition that requires a comprehensive treatment strategy. Pharmacological therapy alone may not ensure lasting behavioural changes, nor prevent muscle mass loss or the risk of malnutrition. In this context, the integration of lifestyle modifications with structured dietary and physical activity interventions is essential. These approaches help preserve lean body mass, reduce the gastrointestinal side effects associated with incretin mimetic drugs, and prevent weight regain after treatment discontinuation. This paper discusses the rationale and supporting evidence for a combined approach, emphasising the key role of personalised nutritional and exercise strategies in the multidisciplinary management of obesity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Gestione dell’obesità nell’era degli incretino-mimetici: ruolo dello stile di vita e degli interventi su dieta ed esercizio fisico

  • 期刊论文

  • 发表日期：

    2025年7月14日

查看全文
  • Marianna Minnetti,
  • Claudia Piciocchi,
  • Francesco Frigerio,
  • Olivia Di Vincenzo,
  • Luca Muzzioli,
  • Eleonora Poggiogalle,
  • Silvia Migliaccio,
  • Lorenzo M. Donini

摘要

The introduction of incretin mimetic drugs, particularly Glucagon-Like Peptide-1 (GLP-1) receptor agonists such as liraglutide and semaglutide, as well as the dual GIP and GLP-1 receptor agonist tirzepatide, has significantly transformed the therapeutic approach to obesity by enabling clinically meaningful weight loss along with associated cardiometabolic benefits. However, obesity remains a chronic, multifactorial, and relapsing condition that requires a comprehensive treatment strategy. Pharmacological therapy alone may not ensure lasting behavioural changes, nor prevent muscle mass loss or the risk of malnutrition. In this context, the integration of lifestyle modifications with structured dietary and physical activity interventions is essential. These approaches help preserve lean body mass, reduce the gastrointestinal side effects associated with incretin mimetic drugs, and prevent weight regain after treatment discontinuation. This paper discusses the rationale and supporting evidence for a combined approach, emphasising the key role of personalised nutritional and exercise strategies in the multidisciplinary management of obesity.